Outlook Therapeutics Regains Nasdaq Compliance, Resolving Delisting Risk
OTLK has more than doubled off its 52-week low of $0.161.
Summary
Outlook Therapeutics has successfully regained compliance with Nasdaq's minimum bid price rule, 5550(a)(2). The company's stock maintained a closing bid price of $1.00 or more for ten consecutive business days, leading Nasdaq to officially close the matter. This positive development resolves a minimum bid price deficiency notice issued on February 18, 2026, and removes a significant delisting risk that was previously highlighted in the company's May 15, 2026 10-Q filing. Regaining compliance is crucial for investor confidence and continued access to public capital markets.
At the time of this announcement, OTLK was trading at $1.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $273.9M. The 52-week trading range was $0.16 to $3.39. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.